Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
Tag: IMagyn050
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
